Diagnostic & Therapeutic Center Of Athens Hygeia Single Member S.A.
- Address
- lock Available on a paid plan
Diagnostic & Therapeutic Center of Athens HYGEIA - Advanced Clinical Research Center
The Diagnostic & Therapeutic Center of Athens HYGEIA Single Member S.A. is a leading clinical research institution specializing in oncology and cardiovascular medicine. The center demonstrates exceptional expertise in conducting complex Phase II and III trials across multiple therapeutic areas, with a particular focus on advanced cancer therapies and cardiovascular disease management.
- Breast Cancer: Hormone receptor-positive and HER2-negative metastatic breast cancer, immunotherapy combinations, and CDK4/6 inhibitor studies
- Gynecologic Oncology: Ovarian, endometrial, and cervical cancers with emphasis on platinum-resistant disease and immunotherapy approaches
- Cardiovascular Disease: Heart failure with preserved and reduced ejection fraction, acute myocardial infarction, and atrial fibrillation
- Head and Neck Cancer: Metastatic and recurrent squamous cell carcinoma with novel targeted therapies
The center has established significant capabilities in cardiovascular outcomes research, conducting trials for heart failure patients with impaired kidney function, acute coronary syndromes, and atrial fibrillation management. Additionally, the facility participates in cutting-edge studies exploring neurodegenerative disease treatments for Alzheimer's disease and metabolic disorders including severe hypertriglyceridemia. The center's research portfolio reflects its commitment to advancing precision medicine through biomarker-driven trials and combination immunotherapy approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 76 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB4active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S7trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic & Therapeutic Center Of Athens Hygeia Single Member S.A.
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 76 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Exemestane | 5 | Unknown | 2023-07-25 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.